Living with very advanced forms of prostate cancer

A new article in the journal Supportive Care in Cancer makes the point that informational needs and resources for men dealing with metastatic, castration-resistant prostate cancer continue to be relatively poor — a fact that we would not disagree with. … READ MORE …

Everolimus + bicalutamide in treatment of CRPC?

A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …

Arno starts Phase II testing of onapristone in men with CRPC

According to a media release issued yesterday, Arno Therapeutics has  moved its investigational drug onapristone into the Phase II part of its initial Phase I/II clinical trial in the treatment of very late stage prostate cancer. … READ MORE …

Recommendations of the Prostate Cancer Clinical Trials Working Group 3

Several readers will be interested in looking through a new article that deals with the recommendations from the Prostate Cancer Clinical Trials Working Group 3 on the development of clinical trials of new drugs to treat castration-resistant prostate cancer (CRPC). … READ MORE …

The role of CT scanning in assessment of progression of men with CRPC

A newly published paper in the journal Cancer seems to be implying that every man with castration-resistant prostate cancer who progresses from non-metastatic to metastatic status (based on a bone scan or other indicators) should also be given a CT scan because of risk for soft tissue metastasis. … READ MORE … >

Is there ANY role for estramustine phosphate in treatment of CRPC today?

The appropriate, individual treatment of men with metastatic and non-metastatic forms of castration-resistant prostate cancer (CRPC) has become vastly more complicated over the past 5 years. … READ MORE …

Does cabazitaxel have targeted potential in late stage prostate cancer?

A research team working just down the street here in Philadelphia thinks cabazitaxel (Jevtana) may have expanded potential in treatment of some men with castration-resistant prostate cancer (CRPC). … READ MORE …